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INTRODUCTION
Actinic keratosis (AK) is a common premalignant skin disease that impairs patients' quality of life (QoL) [1] [2] [3] [4] and causes a significant burden to the health care system [5] [6] [7] [8] [9] . A key cause for AK is cumulative exposure to ultraviolet light. Clinically, AK is described as ''keratotic macules, papules or plaques with superficial scales on a red base'' [2] .
The prevalence of AK is 11-25% worldwide [10] [11] [12] . The largest AK prevalence has been reported in the southern hemisphere [13, 14] , in populations near the equator and in countries with a high proportion of white inhabitants [2] .
AK's prevalence increases with age, for example, 34% and 18% of males and females over the age of 70 had AK in the United Kingdom (UK), respectively [11] . Histologically, AKs are considered to be precursors of squamous cell carcinoma (SCC), because AK can regress, persist unchanged or progress to invasive SCC [2, 15] . Over a decade, 1-16% of AKs progress to invasive SCC [2] .
The incidence of SCC has increased [16, 17] .
In Finland, this increase has been 2.5% per annum [15] and there were 1366 registered new cases of SCC in Finland in 2009 [18] . Nonmelanoma skin cancer (NMSC, including SCC and also basal cell carcinoma of the skin) is among the top five most costly cancers [19] and a major cost driver for health care [9, 20] . Based on Finnish hospital discharge register (FHDR) [21] data with nationwide public health care coverage from 2009, around 19% of incident NMSCs were histologically confirmed SCCs in Finland. 18% of these histologically confirmed SCC patients had an AK diagnosis during the past 10 years. Actinic keratosis lesions are commonly located on the head (75% based on the incident FHDR data from 2009). Typically, multiple lesions are present in a field of UVdamaged skin with subclinical lesions surrounding visible lesions (so-called field cancerization) [2, 9, 15] . SCC risk is higher in patients with more than five AK lesions [22] .
However, SCC development is impossible to predict. It is recommended that multiple AK lesions are treated with field treatment that can target both visible and subclinical lesions [2, 12, 15, [23] [24] [25] [26] [27] [28] [29] [30] [31] .
The goal of AK treatment is to achieve complete clearance (CC) of lesions, thereby potentially preventing the AK lesions from developing into SCC [15, 32] . Finnish AK articles have been published [9, 15, [33] [34] [35] [36] [37] and, generally speaking, Finnish treatment practice seems to be in line with European approaches [2, 38] with one exception: [37] . Diclofenac (Solaraze Ò ) 3% for 12 weeks is used less frequently [37] and is generally considered for older or institutionalized AK patients in Finland.
Newer topical AK treatments include a 6-week treatment with 3.75% imiquimod (Zyclara Ò , head area indication), and 3-or 2-day treatments with ingenol mebutate gel (IngMeb, Picato Ò ) 0.015% for head area or 0.05% for body area, respectively [9, 15] . IngMeb is a pleiotropic effector with a dual action mechanism and short treatment duration. IngMeb-associated skin reactions typically resolve within 2-4 weeks depending on the treated area [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] .
Our study seeks to assess the cost-utility of common first-line treatments for AK field (max. 25 cm 2 ) affecting any body part. The costeffectiveness of AK treatments has not been previously assessed in the Finnish context. Furthermore, to our knowledge, our analysis is the first to include imiquimod 3.75% and IngMebs. national (e.g., [9, 15] ) and international expert opinions (e.g., [62] ), the following structural assumptions were made in the assessment. In the model, the treatments resulted in CC or non-CC after 6 months, and both outcomes could be achieved with or without short-term LSRs. In the case of CC, a patient was at risk of recurrence at 12 months. Non-CC AK was assumed to be treated with MAL ? PDT whereas first-line AK recurrence after CC was retreated with the previous effective treatment.
METHODS

Cost
Efficacy and Safety Inputs
Health effects included in the CUA were CC, 
Quality of Life Inputs
Quality of life scores were applied to patients for the duration of the model. AK and LSRs have a detrimental effect on QoL, whereas successful treatment leads to improvements, the magnitude of which will depend on whether the patient achieves CC [1, 4] . At the time of analysis, the QoL scores by Wilson et al. [3] were most representative values found for the different AK states included in the model. [92, 93] , i [80, 94] , j Imiquimod 5% (assumption), k [89, 91] The QoL scores of Wilson et al. [3] were anchored to Finland using the average EuroQol (EQ-5D-3L) QoL score of 0.776 for Finnish people aged 65-74 years [95] . This resulted in 0.776 QoL for CC and 0.765 QoL for AK (non-CC). These values were considered to be valid regardless of AK site, because the lesion site has not statistically been shown to significantly impact the QoL [96] . The applied QoL impact of LSR was -0.085 [3] and the duration of LSRs is given in Table 1 . After LSR resolution, the QoL was assumed to recover back to the level experienced in the AK health state, until the time of potential CC was reached.
Cost Inputs
The cost estimation was based on Finnish [38] . In the model, 2% of all topical treatments were prescribed in the PC setting (with full secondary care costs in order not to underestimate the base case costs of topicals) and the remaining 98% were prescribed in all between-treatment cost differences for the head area were significant. Also, all between-treatment cost differences for the body area were significant with the exception of insignificant difference between diclofenac and cryosurgery. Figure 2 depicts the deterministic dispersion of costs by treatment and cost type. LSR and recurrence management constituted a minor proportion of total costs. Health care, retreatment and first-line drug were the key cost drivers. Table 3 shows the ICERs based on the treatment indications. The CEEF for AK in face and scalp included only two treatments: imiquimod 5% and IngMeb 0.015% (upper part of Fig. 3 ). IngMeb 0.015% dominated the other AK treatments indicated for the face and scalp area with the exception of imiquimod 5% for which the ICER was estimated at €1933/ QALY gained and MAL ? PDT, which has the ICER of €82,607/QALY gained against IngMeb 0.015% (Table 3 ; Fig. 3 ). IngMeb 0.05% dominated other treatments indicated for trunk and extremities as shown by the costeffectiveness plane in the lower part of Fig. 3 .
Based on the CEAF for AK treatments with face and scalp area indication (upper part of Fig. 4 ), IngMeb 0.015% was the optimal treatment (i.e., treatment with highest expected net benefit) when WTP was between €1933 and 82,607/QALY gained. IngMeb 0.015% was also potentially cost-effective (i.e., €250, and €504 with the WTP of €0, €15,000, €30,000, and €50,000 per QALY gained, respectively. The respective cost-effectiveness probabilities for IngMeb 0.015% were 43%, 54%, 41%, and 31%.
Based on the CEAF for AK treatments indicated for trunk and extremities (lower part of Fig. 4 ), IngMeb 0.05% was the optimal and a potentially cost-effective treatment with all plausible (e.g., €0-50,000/QALY gained) WTP levels. The EVPIs per patient were €0, €58, €169,
€330 with the WTP of €0, €15,000, €30,000, and €50,000 per QALY gained, respectively. The respective cost-effectiveness probabilities for IngMeb 0.05% were 100%, 80%, 71%, and 66%.
Sensitivity Scenarios
Probabilistic mean QALYs and costs of sensitivity analysis scenarios are given in For face and scalp AK, MAL ? PDT was projected to be the most effective treatment, but its effectiveness came with high payer costs.
There was no significant difference in 2-year effectiveness between MAL ? PDT and IngMeb 0.015%, and a high ICER of €82,706/QALY gained was estimated for MAL ? PDT against IngMeb 0.015%. The respective ICER was €28,807/QALY gained in the full societal perspective analysis-the setting which is not recommended to be used alone without the payer perspective [51] . Even though there are no published ICER thresholds in Finland, it seems that ICERs exceeding €50,000/QALY gained are rarely considered cost-effective for other than very severe diseases and that ICERs should be\€20,000/QALY gained for more common and/or less severe conditions, which is in line with, for example, the UK thresholds [61] .
Based on this analysis, MAL ? PDT's 2-year payer costs should be at least 15% lower to meet the €20,000/QALY gained. The result and affordable tendered cost with potential drug sharing were assumed for MAL (for topicals, official list costs were used). Yet, in comparison with commonly used imiquimod 5%, IngMeb 0.015% was significantly more effective and resulted in a low ICER of €1993/QALY gained for the face and scalp AK. The cost-effectiveness of imiquimod 5% was, however, uncertain because IngMeb 0.015% dominated imiquimod 5% when a 1-year time horizon, a particular optimal treatment for all patients, and given that the optimal treatment decision would be an incorrect one for some patients (opportunity cost), the EVPI per patient with €20,000/QALY gained was rather low in comparison to, for example, costs associated with different treatments. This also means that it may not be worthwhile from the perspective of cost-effectiveness to find patients to whom the average optimal treatment is not really optimal.
The assessment of AK field treatment was important for several reasons. First, where multiple AK lesions are present there is likely to be an underlying and surrounding area of actinic damage (field change); the extent of this area may not be evident visually or by physical examination. Second, field change can have a role in the development of SCC or other NMSCs.
Third, cryotherapy is a commonly used lesiondirected therapy that does not target actinic changes in the sun-damaged skin surrounding the individual lesion [2, 30] . Fourth, before IngMeb, there was medical (adherence) need for field directed therapies with shorter and simpler treatment regimens and less long-term irritation and inflammation [31] .
Direct comparative data between the relevant treatment options were not available and thus, CCs were included on the basis of Bayesian network meta-analysis [63] . In comparison with one alternative meta-analysis available [104] that includes IngMeb without any further specification, we chose the metaanalysis assessed by the authorities for the following reasons: IngMeb 0.015% and 0.05% were included and separated (they are essentially different treatments for different indications), and imiquimod 5% for 8 weeks and 3.75% for 6 weeks were included. However, on aggregate level, the results of these metaanalyses concur, and in both analyses, frequently used cryotherapy is inferior.
One for treatment of the AK field [2] . Some studies assessing the economic value or cost-effectiveness of treating AK with different treatment response assessment times have been done [3, 6, [105] [106] [107] [108] [109] [110] [111] [112] [113] . Generally, the treatment of AK has been found to be cost-effective.
However, MAL ? PDT and sometimes cryosurgery treatment have been found to be relatively costly, which is in line with the results of this analysis. Some of the published studies were based on cost estimates and other assumptions that are not applicable or reproducible in Finnish (e.g., [110, 111] ) or other settings [113] . We included a wide spectrum of outcomes. The average time to assess the response was 6 months in the trials and 6 months was also an adequate time to assess CC based on the Finnish clinical practice. We also accounted for the treatment specific time to CC and time with LSR in addition to a 12 months recurrence risk. Furthermore, when considering the European perspective of resources used and associated costs, the Finnish setting represents the average quite well for skin cancers [38] .
This modeled assessment had some key limitations. First, a decision tree approach was chosen as a more appropriate and simpler approach consistent with the nature of AK and its treatments. In particular, the differential timing of treatment responses and LSRs (and also productivity losses in a sensitivity analysis scenario) with different treatments had to be considered, and was included as a distribution.
In Third, the modeling assumed that treatment responses are assessed at 6 months after treatment. However, in real-life clinical practice, the assessment may take place earlier; this assumption was considered plausible since the model accounts for the varying time to treatment response and time with LSR when calculating QALYs. The 6-month interval was based on the mid-point assessment range of clinical trials that were identified for the Bayesian network metaanalysis [63] . Furthermore, a static time point was required for a decision tree structure, to allow all comparisons to be treated equally.
Fourth, patients entered the model when initiating the first-line therapy. IngMeb has the potential to be used more in the PC setting. For that, a scenario with 30% PC use was assessed.
As an extreme sensitivity analysis scenario and to improve result comparability to other settings, all topicals were assumed to be used in the PC setting.
Fifth, all patients were assumed to complete the first course of treatment in the base case analysis because the used efficacy data are based on an intention-to-treat setting, which therefore already incorporated the impact of treatment discontinuations [114, 115] . Also, the treatment response/success was measured in terms of CC (no AK lesions remaining), which is the strictest definition of treatment success, but well in line with the AK treatment objectives. This is easy to understand and may be a less biased outcome in comparison with, e.g., proportion of AK lesions cleared.
Sixth, the study lacked the data for subgroup analysis based on patient characteristics.
Hypothetically speaking, differences in QALYs could be marginally larger for men or for younger than average patients based on their population values [95] . In a longer time horizon modeling including mortality, the potential difference between men and women is likely to be meaningless.
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